youtube_live
Q3 2026 earnings • released • EPS beat +17.88% • Revenue beat +7.88%
See resultschevron_right
LLY:NYSE
Eli Lilly And Co
$1,410.99
arrow_downward
-0.36%(-5.04) 1D
$1,413.00
arrow_upward
+0.14% (+2.01)bedtimeAfter hours
Closed: Nov 2, 4:03:06 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LLY...
Open
$1,393.15
High
$1,421.99
Low
$1,382.02
Mkt. cap
1.33T
Avg. vol.
2.45M
Volume
3.74M
Dividend
0.49%
Quarterly dividend
$1.73
Ex-dividend date
Aug 14, 2026
P/E ratio
45.80
52-wk high
$1,449.68
52-wk low
$850.51
EPS
$30.81
Beta
0.46
Shares outstanding
940.74M
No. of employees
50K
Open
$1,393.15
High
$1,421.99
Low
$1,382.02
Mkt. cap
1.33T
Avg. vol.
2.45M
Volume
3.74M
Dividend
0.49%
Quarterly dividend
$1.73
Ex-dividend date
Aug 14, 2026
P/E ratio
45.80
52-wk high
$1,449.68
52-wk low
$850.51
EPS
$30.81
Beta
0.46
Shares outstanding
940.74M
No. of employees
50K
News stories
From web sources and news partners
Yahoo Finance
·
6 hours ago
Eli Lilly Stock: Is It Still a Buy at $1,400?
Seeking Alpha
·
7 hours ago
Eli Lilly: Softer Growth Ahead (Rating Downgrade) (NYSE:LLY)
GuruFocus
·
10 hours ago
Eli Lilly Stocks Move Lower With Higher Target Facing a Volume-P
Indianapolis Business Journal
·
12 hours ago
Lilly combines U.S. and international commercial units into single division
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Co
CEODavid A. Ricks
Employees50K
Founded1876
HeadquartersIndianapolis, Indiana, United States
SectorPharmaceutical industry
Websitelilly.com
Analyst ratings
Based on 24 analysts giving stock ratings to LLY in the past 3 months
Strong buy
Buy
22
Hold
1
Sell
1
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for LLY in the last 3 months.
Highest
Current $1,410.99
$1,650.00 (+16.94%)
Average
$1,508.70 (+6.92%)
Lowest
$940.00 (-33.38%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
David Risinger Leerink Partners | Buy | Maintained | $1,508.00 | +6.9% | 11/02/2026 |
Carter Gould Cantor Fitzgerald | Buy | Maintained | $1,600.00 | +13.4% | 11/02/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $1,650.00 | +16.9% | 11/02/2026 |
Ilya Zubkov Freedom Capital Markets | Buy | Maintained | $1,600.00 | +13.4% | 10/30/2026 |
Terence Flynn Morgan Stanley | Buy | Maintained | $1,596.00 | +13.1% | 10/30/2026 |
Srikripa Devarakonda Truist Financial | Buy | Maintained | $1,612.00 | +14.2% | 10/30/2026 |
Louise Chen Scotiabank | Buy | Maintained | $1,605.00 | +13.7% | 10/30/2026 |
Asad Haider Goldman Sachs | Buy | Reiterated | $1,573.00 | +11.5% | 10/30/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | $1,550.00 | +9.9% | 10/30/2026 |
Trung Huynh RBC Capital | Buy | Reiterated | $1,600.00 | +13.4% | 10/29/2026 |
Chris Schott J.P. Morgan | Buy | Reiterated | $1,650.00 | +16.9% | 10/30/2026 |
Michael Yee UBS | Buy | Reiterated | $1,625.00 | +15.2% | 10/30/2026 |
Mohit Bansal Wells Fargo | Buy | Maintained | $1,500.00 | +6.3% | 10/29/2026 |
Jason Gerberry Bank of America Securities | Buy | Reiterated | $1,497.00 | +6.1% | 10/29/2026 |
Geoff Meacham Citi | Buy | Maintained | $1,650.00 | +16.9% | 10/30/2026 |
Akash Tewari Jefferies | Buy | Reiterated | $1,610.00 | +14.1% | 10/29/2026 |
Emily Field Barclays | Buy | Maintained | $1,400.00 | -0.8% | 10/29/2026 |
Courtney Breen Bernstein | Buy | Reiterated | $1,450.00 | +2.8% | 10/26/2026 |
Kerry Holford Berenberg Bank | Buy | Maintained | $1,400.00 | -0.8% | 10/20/2026 |
Steve Scala TD Cowen | Buy | Maintained | $1,250.00 | -11.4% | 10/01/2026 |
Umer Raffat Evercore ISI | Hold | Maintained | - | - | 09/23/2026 |
Jose Luis Pascual JLPascual | Hold | Maintained | $1,035.00 | -26.6% | 09/23/2026 |
Seamus Fernandez Guggenheim | Buy | Reiterated | $1,284.00 | -9% | 09/17/2026 |
Luisa Hector Berenberg Bank | Buy | Upgraded | $1,400.00 | -0.8% | 09/14/2026 |
Rajesh Kumar HSBC | Sell | Maintained | $940.00 | -33.4% | 09/10/2026 |
Nico Chen DBS | Buy | Maintained | $1,550.00 | +9.9% | 08/25/2026 |
Harry Gillis Berenberg Bank | Hold | Maintained | $1,220.00 | -13.5% | 08/13/2026 |
Alexandria Hammond Wolfe Research | Buy | Maintained | $1,350.00 | -4.3% | 05/21/2026 |
James Shin Deutsche Bank | Buy | Reiterated | $1,285.00 | -8.9% | 05/07/2026 |
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$7.48 / $6.35
+17.88%beat
arrow_upward
Revenue / Est. (USD)
24.40B / 22.62B
+7.88%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 19.29B | 19.80B | 22.97B | 24.40B |
Cost of goods sold | 3.37B | 3.58B | 3.27B | 3.93B |
Cost of revenue | 3.37B | 3.58B | 3.27B | 3.93B |
Research and development expenses | 3.80B | 3.51B | 3.82B | 4.25B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.46B | 2.93B | 3.43B | 3.12B |
Operating expense | 7.26B | 6.44B | 7.25B | 7.37B |
Total operating expenses | 10.63B | 10.02B | 10.52B | 11.30B |
Operating income | 8.66B | 9.78B | 12.46B | 13.09B |
Other non operating income | 181.20M | 170.00M | 561.00M | 13.00M |
EBT including unusual items | 8.27B | 8.85B | 9.25B | 8.41B |
EBT excluding unusual items | 8.89B | 9.71B | 12.73B | 12.89B |
Income tax expense | 1.63B | 1.45B | 2.15B | 1.96B |
Effective tax rate | 19.70% | 16.43% | 23.27% | 23.26% |
Other operating expenses | - | - | - | - |
Net income | 6.64B | 7.40B | 7.10B | 6.45B |
Net profit margin | 34.41% | 37.36% | 30.88% | 26.44% |
Earnings per share | 7.54 | 8.55 | 8.38 | 7.48 |
Interest and investment income | 672.40M | - | - | - |
Interest expense | -153.30M | -332.00M | -345.00M | -378.00M |
Net interest expenses | 519.10M | -332.00M | -345.00M | -378.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 9.25B | 10.29B | 12.99B | 13.64B |
Gain or loss from assets sale | -180.00M | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events